ReviewACS nano2026
New Frontiers in Contrast-Enhanced Ultrasound for Cancer Imaging.
Review in ACS nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Preclinical evaluation of PSMA-targeted ultrasound contrast agents in an orthotopic model of prostate cancer in rabbits.Bioactive materials · 2027Article
- The role of contrast-enhanced transcranial color-coded real-time sonography combined with the common carotid artery compression test in preoperative evaluation of anterior communicating artery patency in patients with insufficient temporal bone windows.Frontiers in neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanobubbles (NBs) are increasingly recognized as the next generation of ultrasound contrast agents that can provide alternate avenues for the advancement of cancer imaging and therapy. Compared to currently clinically viable microbubbles that are limited to the vasculature because of their size, nanobubbles with diameters ranging from 200 to 500 nm can potentially target the perivascular and possibly extravascular compartments. Their polymeric, lipid, or hybrid shells can be engineered to tune stability, increase circulation time, and support surface functionalization with ligands to facilitate receptor-directed binding. Preclinical studies show that NBs can extend ultrasound imaging windows, improve sensitivity, and increase tumor-to-background contrast across different types of cancers. NBs can also be formulated with secondary reporters that allow their combination with other imaging modalities, such as optical (photoacoustic and fluorescence) and magnetic resonance imaging. However, several challenges need to be overcome to allow the clinical translation of NBs, such as acoustic optimization and standardization, formulation and manufacturing reproducibility, and comprehensive safety characterization. Addressing these barriers will be essential to establishing NBs as clinically viable agents. Here, we summarize recent advances in NB design and functionalization, review key preclinical oncology applications, and discuss translational priorities to support their integration into precision oncology clinical workflows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.